Food Allergy Awareness Week 2024: How can new treatments target an unmet need?
Pharmaceutical Technology
MAY 16, 2024
IgGenix is planning to initiate a clinical trial later this year investigating its peanut allergy monoclonal antibody IGXN001.
Maternal Antibodies: How Allergies Can be Passed from Mothers to Children
XTalks
NOVEMBER 4, 2020
It has long been known that mothers greatly influence the development of the growing fetus by not only providing nutrients through the placenta, but also a growing list of biological elements including beneficial antibodies, gut bacteria and now, allergies. Related: Red Meat Allergy Test Gets FDA Clearance.
Allergies 
98
98 Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Re-examining antibodies' role in childhood allergies
Medical Xpress
DECEMBER 2, 2022
The presence of food-specific IgA antibodies in the gut does not prevent peanut or egg allergies from developing in children, according to a Northwestern Medicine study published in Science Translational Medicine.
Allergies 81
81 
Asthma Drug Xolair Wins FDA Approval as First Treatment for Multiple Food Allergies
XTalks
FEBRUARY 26, 2024
The class of IgE-mediated food allergies includes 160 foods, with peanuts, milk, eggs, wheat, soy and tree nuts being the most common ones. According to the Centers for Disease Control and Prevention (CDC), almost six percent of people in the US in 2021 had a food allergy. However, the treatment is restricted to peanut allergy.
Allergies 100
100 
IgGenix Launches with $10 Million to Develop Therapeutics for Severe Allergies
BioSpace
AUGUST 4, 2020
emerged from stealth mode with $10 million in Series A financing and a goal to advance the company’s novel antibody therapeutics platform for the treatment of food and non-food allergies, as well as other severe allergic conditions. Startup IgGenix, Inc.
Allergies 82
82 
NIAID drops Lilly antibody from ACTIV-3 COVID-19 trial
pharmaphorum
OCTOBER 27, 2020
Eli Lilly says no more patients will be treated with its COVID-19 therapy bamlanivimab in a trial run by the US National Institute of Allergy and Infectious Diseases (NIAID), as results to date suggest it is unlikely to be effective. The post NIAID drops Lilly antibody from ACTIV-3 COVID-19 trial appeared first on.
Antibody 105
105 
One dose of Regeneron’s COVID antibody protects for eight months
pharmaphorum
NOVEMBER 8, 2021
A single dose of the COVID-19 monoclonal antibody therapy developing Regeneron reduced the risk of contracting the virus by around 82% for up to eight months, according to new trial data. The post One dose of Regeneron’s COVID antibody protects for eight months appeared first on.
Antibody 105
105 
US buys Lilly COVID antibody, as effectiveness questions remain
pharmaphorum
OCTOBER 28, 2020
Our goal is to ensure that Lilly antibody treatments are available to patients who need them, no matter where they live. “As As long as supply of neutralising antibodies is constrained, we believe the only way to ensure equitable access is for Lilly to contract directly with governments and pan-national philanthropic organisations. “As
Antibody 104
104 
Antibody treatment improves chronic food allergy symptoms in young adults, study finds
Medical Xpress
DECEMBER 22, 2022
A weekly dose of dupilumab, a monoclonal antibody, led to a reduction of symptoms and tissue improvement in young adults and adolescents with eosinophilic esophagitis (EoE), according to a new study published in the New England Journal of Medicine.
Antibody 75
75 
FDA grants emergency licence for Lilly’s COVID-19 antibody combo
pharmaphorum
FEBRUARY 10, 2021
The FDA has granted an emergency licence for Eli Lilly’s COVID-19 antibody combination therapy, to reduce chances of high-risk patients progressing from mild to moderate disease to more severe symptoms that may need hospital treatment. There are a range of other antibody therapies in various stages of development.
Antibody 96
96 
Large NIH clinical trial will test polyclonal antibody therapeutic for COVID-19
Scienmag
APRIL 21, 2021
Credit: NIAID A Phase 2/3 trial to evaluate a new fully-human polyclonal antibody therapeutic targeted to SARS-CoV-2, called SAB-185, has begun enrolling non-hospitalized people with mild or moderate cases of COVID-19.
Antibody 81
81 
UTMB study shows common antibody therapy has anti-SARS-CoV-2 Antibodies
Scienmag
APRIL 25, 2022
GALVESTON, Texas – Researchers at the University of Texas Medical Branch recently confirmed the presence of neutralizing antibodies to SARS–COV-2 in a common subcutaneous antibody therapy (Hizentra) used to treat immunocompromised or immunodeficient patients, citing its protective benefits to the immunocompromised patient community.
Antibody 61
61 
Are we entering the era of biologics for COPD?
Pharmaceutical Technology
JANUARY 8, 2023
In 2023, the pharmaceutical industry will mark 20 years since Xolair, an anti-IgE antibody, became the first biologic approved to treat asthma. Since then, the US FDA, EMA, and other agencies have approved several biologic antibodies targeting the inflammatory cytokines IL-4, IL-13, IL-5, and others for asthma. Ongoing efforts.
Antibody 298
298 
HIV vaccines suffer setbacks but new approaches could turn the tide
Pharmaceutical Technology
FEBRUARY 3, 2023
Additionally, advances in the study of broadly neutralising antibodies (bNAbs) have led to new candidates being studied in early trials. The study was done in collaboration with the United States Army Medical Research and Development Command (USAMRDC), the Thai Ministry of Health, and others.
Vaccine 293
293 
New serological assay provides rapid, accurate testing for SARS-CoV-2 antibodies
Scienmag
DECEMBER 10, 2020
Using optical biosensor technology, the test provides quantitative measurements of antibodies in blood plasma in less than 20 minutes Credit: Carolyn Lagattuta Researchers at UC Santa Cruz have developed a novel serological assay for the detection of antibodies to SARS-CoV-2, the coronavirus that causes COVID-19.
Antibody 98
98 
COVID-19 antibodies persist at least nine months after infection
Scienmag
JULY 19, 2021
Credit: Andrea Crisanti Testing of an entire Italian town shows antibody levels remain high nine months after SARS-CoV-2 infection, whether symptomatic or asymptomatic.
Antibody 100
100 
Antibody cocktails at low doses could be more effective at treating COVID-19
Scienmag
NOVEMBER 19, 2020
Credit: University of North Carolina/Megan May Pairs of antibodies may be more effective than single antibodies at preventing and treating COVID-19, according to a new study by researchers at the University of North Carolina at Chapel Hill and The Rockefeller University in New York.
Antibody 95
95 
Patients with recently discovered antibodies have more severe myasthenia gravis
Scienmag
AUGUST 18, 2020
Credit: Phil Jones, Senior Photographer, Augusta University A study of 181 patients at 16 sites across the country who test negative for two antibodies long known to cause muscle-weakening myasthenia gravis, found that about 15% test positive for one of two newly discovered antibodies that also attack the point of communication between nerves and muscle. (..)
Antibody 85
85 
8 Of The Most Common Foods Allergies – Do You Have One?
Delveinsight
DECEMBER 23, 2020
As per the Food Allergy Research & Education, in the US, each year, around 200,000 people require emergency medical care for allergic reactions to food. Food allergy is a specific immune response to certain food items that it considers harmful. The symptoms of food allergy vary from person to person and can also differ over time.
Allergies 52
52 
More malaria hope as antibody protects against infection
pharmaphorum
AUGUST 12, 2021
A single dose of a monoclonal antibody developed by scientists at the US National Institutes of Health (NIH) has provided protection for people exposed to malaria parasites for up to nine months. The post More malaria hope as antibody protects against infection appeared first on.
Antibody 64
64 
New ‘atlas’ charts how antibodies attack spike protein variants
Scienmag
JULY 23, 2021
Antibodies capable of neutralizing multiple SARS-CoV-2 strains can inform strategies for broadly protective COVID-19 booster vaccines As the SARS-CoV-2 virus that causes COVID-19 continues to evolve, immunologists and infectious diseases experts are eager to know whether new variants are resistant to the human antibodies that recognized initial versions (..)
Antibody 75
75 
NIAID Halts Eli Lilly COVID-19 Antibody Trial
The Pharma Data
OCTOBER 27, 2020
The NIH’s National Institute of Allergy and Infectious Diseases (NIAID) has halted a clinical trial evaluating Eli Lilly’s investigational monoclonal antibody, LY-CoV555 (bamlanivimab), in combination with remdesivir for the treatment of COVID-19 patients. Source link.
Antibody 52
52 
Dried blood spot sampling offers inexpensive way to widen access to antibody testing for COVID-19
Scienmag
OCTOBER 6, 2020
Credit: University of Birmingham Using dried blood spot samples (DBS) is an accurate alternative to venous blood in detecting SARS-CoV-2 antibody tests, a new study by immunology experts at the University of Birmingham has found.
Antibody 83
83 
2022 in review: Drug development milestones for tropical diseases
Pharmaceutical Technology
DECEMBER 16, 2022
The monoclonal antibody (mAb) CIS43LS, derived from the antibody CIS43, targets the Plasmodium falciparum circumsporozoite protein (PfCSP), and is being studied by the National Institute of Allergy and Infectious Diseases (NIAID). Apart from vaccines, other approaches for preventing malaria are also being studied.
Development 264
264 Antibody response may drive COVID-19 outcomes
Scienmag
FEBRUARY 18, 2021
Researchers at the Ragon Institute of MGH, MIT and Harvard and Massachusetts General Hospital show that levels of specific antibodies developed in the immune response may influence COVID-19 outcomes in both children and adults.
Antibody 74
74 
WRAIR, Duke scientists identify of monoclonal antibodies efficacy against malaria
Scienmag
MARCH 5, 2021
Scientists at Walter Reed Army Institute of Research, in a collaboration the Duke University, have confirmed that monoclonal antibodies can be an effective tool in the global fight against malaria.
Scientist 74
74 
Flexible targets help immune system make finely-tuned antibodies
Scienmag
AUGUST 24, 2020
An in-depth Garvan study of how the immune system generates effective antibodies provides new insights for vaccine design. Credit: Dr Ofir Shein-Lumbroso, Garvan Institute of Medical Research An in-depth Garvan study of how the immune system generates effective antibodies provides new insights for vaccine design.
Antibody 67
67 
Antibodies help identify women protected from placental malaria
Scienmag
JUNE 29, 2021
Six antibody features help protect pregnant women against placental malaria infections, and could be used to identify women at risk of the disease and related complications Six antibody characteristics could help scientists identify which pregnant women are at risk of placental malaria infections, finds a study published today in eLife.
Antibody 65
65 
No drugs for prions: could new approaches alleviate therapeutic scarcity?
Pharmaceutical Technology
AUGUST 5, 2022
This list includes the monoclonal antibody (mAb) PRN100 developed at University College London (UCL) and ALX-002, a treatment developed by Allyx Therapeutics that is also being studied for Alzheimer’s disease. There are only a few antibodies that can specifically recognize the (abnormal) version of the prion protein.
Drugs 299
299 
Altered ‘coat’ disguises fatal brain virus from neutralizing antibodies
Scienmag
NOVEMBER 20, 2020
— A genetic modification in the ‘coat’ of a brain infection-causing virus may allow it to escape antibodies, according to Penn State College of Medicine researchers. HERSHEY, Pa. They say testing people for this and other viral mutations may help identify patients at risk for developing a fatal brain disease.
Antibody 71
71 
Lilly’s antibody for COVID-19 protection starts nursing home trial
pharmaphorum
AUGUST 3, 2020
While the world waits an effective coronavirus vaccine, Eli Lilly has started late-stage human testing an antibody drug as an alternative way to prevent viral transmission in high-risk locations. The post Lilly’s antibody for COVID-19 protection starts nursing home trial appeared first on. Results are due before the end of the year.
Nurses 59
59 
US experts trial AZ’s long-acting COVID-19 antibody combination
pharmaphorum
FEBRUARY 9, 2021
An international trial led by US experts is to begin testing AstraZeneca’s long-acting antibody combination therapy to treat COVID-19. It is sponsored by the US-government funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
Antibody 52
52 Accuracy of commercial antibody kits for SARS-CoV-2 varies widely
Scienmag
SEPTEMBER 25, 2020
There is wide variation in the performance of commercial kits for detecting antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), according to a study published September 24 in the open-access journal PLOS Pathogens by Jonathan Edgeworth and Blair Merrick of Guy’s and St Thomas’ NHS Foundation Trust, Suzanne Pickering (..)
Antibody 67
67 
Trial of Antibody Drug for COVID-19 Stopped for Lack of Effectiveness
The Pharma Data
OCTOBER 27, 2020
Trial of Antibody Drug for COVID-19 Stopped for Lack of Effectiveness. 27, 2020 — Testing of the Eli Lilly antibody drug for hospitalized COVID-19 patients has been halted because the treatment does not help them recover from their infection. Professional. TUESDAY, Oct. But the U.S.
Antibody 52
52 
Antibody binding-site conserved across COVID-19 virus variants
Scienmag
APRIL 9, 2021
The structural revelation could have implications as a therapeutic target in all SARS-CoV-2 variants Credit: Kelly Lab/Penn State A tiny protein of SARS-CoV-2, the coronavirus that gives rise to COVID-19, may have big implications for future treatments, according to a team of Penn State researchers.
Antibody 93
93 
FDA committee recommends AstraZeneca and Sanofi’s RSV prophylactic nirsevimab
Pharmaceutical Technology
JUNE 9, 2023
Also known as palivizumab, Sobi ‘s Synagis was the first FDA-approved monoclonal antibody used in children at high risk of RSV disease. Marketed under the name Beyfortus in the EU, nirsevimab is a long-acting human recombinant monoclonal antibody. The single seasonal dosing of the drug is a large advance, he noted.
FDA Approval 147
147 
Antibody responses in COVID-19 patients could guide vaccine design
Scienmag
SEPTEMBER 11, 2020
Credit: NIAID, 2020 A comprehensive analysis of antibody responses in coronavirus disease 2019 (COVID-19) patients could inform the development of an effective vaccine, according to a study published September 10 in the open-access journal PLOS Pathogens by Chao Wu and Rui Huang of Nanjing University Medical School, and colleagues.
Antibody 61
61 
Temperature-stable tuberculosis vaccine safe, prompts immune response in first-in-human trial
Medical Xpress
MARCH 6, 2023
A clinical trial testing a freeze-dried, temperature-stable experimental tuberculosis (TB) vaccine in healthy adults found that it was safe and stimulated both antibodies and responses from the cellular arm of the immune system. A non-temperature stable form of the candidate previously had been tested in several clinical trials.
Valneva eyes first place in chikungunya vaccine race
pharmaphorum
DECEMBER 5, 2022
The French biotech says VLA1553 met its objective in the phase 3 study, with 99% of patients exhibiting an antibody response against the virus 12 months after receiving a single dose of the shot, with no evidence of a tailing off in levels in the last six months. It will continue for up to five years.
Vaccine 98
98 
Zydus starts Phase II COVID-19 vaccine trial; Taysha raises $95M; FDA declines DBV’s peanut allergy patch; Combating COVID-19 with decoy target
Delveinsight
AUGUST 6, 2020
Scientists have already isolated many highly potent neutralizing antibodies from patients who recovered from COVID-19. These antibodies defend a cell from infection by squarely preventing the pathogen’s biological activities. FDA turns back peanut allergy patch of DBV Technologies. The agency raised no safety concerns.
Allergies 53
53 
Patients taking long-term opioids produce antibodies against the drugs
Scienmag
AUGUST 17, 2020
. — University of Wisconsin-Madison scientists have discovered that a majority of back-pain patients they tested who were taking opioid painkillers produced anti-opioid antibodies. These antibodies may contribute to some of the negative side effects of long-term opioid use.
Antibody 50
50 Low on antibodies, blood cancer patients can fight off COVID-19 with T cells
Scienmag
MAY 27, 2021
New Penn Medicine study shows how T cells compensate when other immune cells go down PHILADELPHIA–Antibodies aren’t the only immune cells needed to fight off COVID-19 — T cells are equally important and can step up to do the job when antibodies are depleted, suggests a new Penn Medicine study of blood cancer patients with […]. (..)
Antibody 54
54 
Scientists reveal details of antibodies that work against Zika virus
Scienmag
FEBRUARY 25, 2021
Research from the California Institute of Technology shows exactly how antibodies stick to and block the Zika virus, which will inform vaccine development Credit: Image courtesy of Shannon Esswein.
Antibody 52
52 
NIAID Halts Eli Lilly COVID-19 Antibody Trial | 2020-10-28
The Pharma Data
OCTOBER 26, 2020
The NIH’s National Institute of Allergy and Infectious Diseases (NIAID) has halted a clinical trial evaluating Eli Lilly’s investigational monoclonal antibody, LY-CoV555 (bamlanivimab), in combination with remdesivir for the treatment of COVID-19 patients.
Antibody 40
40 
Let's personalize your content